Filing Flows

Filing Flows › Starling Oncology (STLN) › Next earnings date

Starling Oncology (STLN) earnings: missed the estimate

Starling Oncology (STLN) reported on Nov 5, 2026 and missed the EPS estimate: −$0.13 against −$0.05 (-160.0%). Revenue was $170M for Q3 2026, +24% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−160.0% vs estimate
Beat rate40%

The last report

Starling Oncology reported revenue of $170M for the third quarter 2026 (+24% Y/Y), net loss $15.7M: Specialty Pharmacy $109M, Patient services $60.0M. How it makes money → · Every quarter →

Starling Oncology: EPS against the estimate, last 5 reportsStarling Oncology: EPS against the estimate, last 5 reportsEstimateReported−$0.11−$0.14Nov 25−$0.09−$0.06Mar 26−$0.09−$0.02May 26−$0.06−$0.08Aug 26−$0.05−$0.13Nov 26
Latest (Nov 26): Estimate −$0.05, Reported −$0.13.

Starling Oncology's latest quarter

Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Starling Oncology beat earnings?

Starling Oncology (STLN) reported on Nov 5, 2026 and missed the EPS estimate: −$0.13 against −$0.05 (-160.0%).

When does STLN report earnings?

The next date is not set yet.

Does Starling Oncology usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.